Neurofibromatosis Therapeutic Acceleration Program (NTAP) initiatives are informed by a clear understanding of the challenges faced by drug companies who work in rare disorders.

Based on early engagement with industry partners, we are actively working to ensure the essential data and resources are in place to de-risk pNF therapeutic programs and remove obstacles that could otherwise delay new therapies reaching the market.

As well, we actively support collaboration between pNF investigators and industry to help refine research strategies and access the best available resources.